@article { author = {Chegni, Hamid and Hassan, Zuhair M and Nisini, Roberto and Ebrahimi, Marzieh and Sabouni, Farzaneh}, title = {Preliminary In Vitro Effects of CD8+ T Lymphocyte Specific for the CD20 Alternative Splicing D393-CD20 Peptide Expressed on Burkitt Lymphoma Cells}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {20}, number = {8}, pages = {2563-2568}, year = {2019}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {10.31557/APJCP.2019.20.8.2563}, abstract = {The effective discovery of clinically relevant tumor antigens holds a fundamental role for the development ofnew diagnostic tools and anticancer immunotherapies. D393-CD20 mRNA is absent from normal resting B cells butpresent in various malignant or transformed B cells. CD8+T lymphocytes play a central role in immunity to cancer.In this study, we want use from T CD8+ against D393-CD20 for effect in RAMOS cell line. After isolation andexpanding of specific TCD8 + Lymphocyte against D393-CD20 antigen, for examining the effect of specialized Tlymphocyte clone of D393-CD20 antigen on RAMOS cell line, we co-cultured them together, and the rate of apoptosiswere examined by flow cytometry and cytotoxicity techniques by using MTT technique. We observed that specializedTCD8+ lymphocyte of D393-CD20 antigen can induce apoptosis in malignant B-lymphocytes, and this antigen canbe a proper target for immunotherapy.}, keywords = {CD8+ T Lymphocyte,alternative splicing,D393-CD20 peptide,Burkitt lymphoma}, url = {https://journal.waocp.org/article_88711.html}, eprint = {https://journal.waocp.org/article_88711_b1bcfc6ba0bf541ec503316325ea8fa7.pdf} }